In Vitro Diagnostics Business Outlook, Volume 3, Issue 3 - Clinical Chemistry

4 Jul 2024

Categories:

In Vitro Diagnostics Business Outlook is a bimonthly publication with six issues annually.

In Vitro Diagnostics Business Outlook offers information and data that you cannot get anywhere else, including:

Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
A comprehensive view of the IVD market with test categories covered and company briefs
M&A activities, selected partnerships & collaborations, partnership deals, and more
Industry & region watch to help tailor strategies
Analysis of news and events and reporting on news not easily available

Table of Contents

Market Analysis: Clinical Chemistry
- Overview of Clinical Chemistry Market
- Market Outlook
  - Major Product Activity
- Regional Market
- Top Company Briefs
  - Roche
  - Abbott
  - Danaher
Executive News Briefing
- Cue Health Calls It Quits
- Allenz Health Secures $60 Million in Funding
- Next Gen Diagnostics Welcomes New Scientific Advisory Board Member
- Next Gen Diagnostics Opens First U.S. Laboratory
Financial Highlights: bioMérieux & Sekisui Diagnostics
Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Mergers and Acquisitions
- Partnerships and Collaborations
Industry Watch
- COVID-19/Flu Update
Region Watch
Broad-based Company Announcements
- Announcements
  - QIAGEN Launches Gastrointestinal Molecular Panel in the United States
  - Illumina Spins Off Grail
  - QIAGEN Discontinues NeuMoDx System
  - DiaSorin Nabs Clearance for LIAISON PLEX Blood Culture Yeast Assay
  - Genetic Signatures Granted FDA Clearance for GI Kit

Attachments